Gastric Cancer - Pipeline Review, H1 2018

  • ID: 4529326
  • Report
  • 1283 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • Bicycle Therapeutics Ltd
  • EOS Biosciences Inc
  • Incyte Corp
  • Mersana Therapeutics Inc
  • Rhizen Pharmaceuticals SA
  • MORE
Gastric Cancer - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Pipeline Review, H1 2018, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights:

This latest pipeline guide Gastric Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 14, 80, 99, 11, 97, 17 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 9, 3, 1, 9 and 2 molecules, respectively.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3SBio Inc
  • Bicycle Therapeutics Ltd
  • EOS Biosciences Inc
  • Incyte Corp
  • Mersana Therapeutics Inc
  • Rhizen Pharmaceuticals SA
  • MORE
Introduction

Gastric Cancer - Overview

Gastric Cancer - Therapeutics Development

Gastric Cancer - Therapeutics Assessment

Gastric Cancer - Companies Involved in Therapeutics Development

Gastric Cancer - Drug Profiles

Gastric Cancer - Dormant Projects

Gastric Cancer - Discontinued Products

Gastric Cancer - Product Development Milestones

Appendix

List of Tables

Table 1: Number of Products under Development for Gastric Cancer, H1 2018

Table 2: Number of Products under Development by Companies, H1 2018

Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Table 7: Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Table 8: Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Table 9: Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Table 10: Number of Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Table 11: Number of Products under Development by Companies, H1 2018 (Contd..9), H1 2018

Table 12: Number of Products under Development by Companies, H1 2018 (Contd..10), H1 2018

Table 13: Number of Products under Development by Universities/Institutes, H1 2018

Table 14: Products under Development by Companies, H1 2018

Table 15: Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Table 16: Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Table 17: Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Table 18: Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Table 19: Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Table 20: Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Table 21: Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Table 22: Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Table 23: Products under Development by Companies, H1 2018 (Contd..9), H1 2018

Table 24: Products under Development by Companies, H1 2018 (Contd..10), H1 2018

Table 25: Products under Development by Companies, H1 2018 (Contd..11), H1 2018

Table 26: Products under Development by Companies, H1 2018 (Contd..12), H1 2018

Table 27: Products under Development by Companies, H1 2018 (Contd..13), H1 2018

Table 28: Products under Development by Companies, H1 2018 (Contd..14), H1 2018

Table 29: Products under Development by Companies, H1 2018 (Contd..15), H1 2018

Table 30: Products under Development by Companies, H1 2018 (Contd..16), H1 2018

Table 31: Products under Development by Companies, H1 2018 (Contd..17), H1 2018

Table 32: Products under Development by Companies, H1 2018 (Contd..18), H1 2018

Table 33: Products under Development by Universities/Institutes, H1 2018

Table 34: Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Table 35: Number of Products by Stage and Target, H1 2018

Table 36: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Table 37: Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018

Table 38: Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018

Table 39: Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018

Table 40: Number of Products by Stage and Target, H1 2018 (Contd..5), H1 2018

Table 41: Number of Products by Stage and Target, H1 2018 (Contd..6), H1 2018

Table 42: Number of Products by Stage and Mechanism of Action, H1 2018

Table 43: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018

Table 44: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..2), H1 2018

Table 45: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..3), H1 2018

Table 46: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..4), H1 2018

Table 47: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..5), H1 2018

Table 48: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..6), H1 2018

Table 49: Number of Products by Stage and Route of Administration, H1 2018

Table 50: Number of Products by Stage and Molecule Type, H1 2018

Table 51: Gastric Cancer - Pipeline by 3SBio Inc, H1 2018

Table 52: Gastric Cancer - Pipeline by AbbVie Inc, H1 2018

Table 53: Gastric Cancer - Pipeline by AbGenomics International Inc, H1 2018

Table 54: Gastric Cancer - Pipeline by Abion Inc, H1 2018

Table 55: Gastric Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2018

Table 56: Gastric Cancer - Pipeline by ADC Therapeutics SA, H1 2018

Table 57: Gastric Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018

Table 58: Gastric Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H1 2018

Table 59: Gastric Cancer - Pipeline by Alteogen Inc, H1 2018

Table 60: Gastric Cancer - Pipeline by Ambrx Inc, H1 2018

Table 61: Gastric Cancer - Pipeline by amcure GmbH, H1 2018

Table 62: Gastric Cancer - Pipeline by Amgen Inc, H1 2018

Table 63: Gastric Cancer - Pipeline by ANP Technologies Inc, H1 2018

Table 64: Gastric Cancer - Pipeline by Antikor Biopharma Ltd, H1 2018

Table 65: Gastric Cancer - Pipeline by arGEN-X BV, H1 2018

Table 66: Gastric Cancer - Pipeline by Array BioPharma Inc, H1 2018

Table 67: Gastric Cancer - Pipeline by Asana BioSciences LLC, H1 2018

Table 68: Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H1 2018

Table 69: Gastric Cancer - Pipeline by Astellas Pharma Inc, H1 2018

Table 70: Gastric Cancer - Pipeline by AstraZeneca Plc, H1 2018

Table 71: Gastric Cancer - Pipeline by Atara Biotherapeutics Inc, H1 2018

Table 72: Gastric Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018

Table 73: Gastric Cancer - Pipeline by Avipep Pty Ltd, H1 2018

Table 74: Gastric Cancer - Pipeline by Basilea Pharmaceutica Ltd, H1 2018

List of Figures

Figure 1: Number of Products under Development for Gastric Cancer, H1 2018

Figure 2: Number of Products under Development by Companies, H1 2018

Figure 3: Number of Products under Development by Universities/Institutes, H1 2018

Figure 4: Number of Products by Top 10 Targets, H1 2018

Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018

Figure 6: Number of Products by Top 10 Mechanism of Actions, H1 2018

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Figure 8: Number of Products by Top 10 Routes of Administration, H1 2018

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Figure 10: Number of Products by Top 10 Molecule Types, H1 2018

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 3SBio Inc
  • AbbVie Inc
  • AbGenomics International Inc
  • Abion Inc
  • Adaptimmune Therapeutics Plc
  • ADC Therapeutics SA
  • Advenchen Laboratories LLC
  • Allist Shanghai Pharmaceutical Technology Co Ltd
  • Alteogen Inc
  • Ambrx Inc
  • amcure GmbH
  • Amgen Inc
  • ANP Technologies Inc
  • Antikor Biopharma Ltd
  • arGEN-X BV
  • Array BioPharma Inc
  • Asana BioSciences LLC
  • Aslan Pharmaceuticals Pte Ltd
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • Aurigene Discovery Technologies Ltd
  • Avipep Pty Ltd
  • Basilea Pharmaceutica Ltd
  • Bayer AG
  • BeiGene Ltd
  • Beijing Hanmi Pharmaceutical Co Ltd
  • Betta Pharmaceuticals Co Ltd
  • Bicycle Therapeutics Ltd
  • Biocon Ltd
  • Bioleaders Corp
  • BioLineRx Ltd
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Camel-IDS NV
  • Cancer Prevention Pharmaceuticals Inc
  • CARsgen Therapeutics Ltd
  • Cascadian Therapeutics Inc
  • CBT Pharmaceuticals Inc
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Cellestia Biotech AG
  • Celltrion Inc
  • Celon Pharma SA
  • Chipscreen Biosciences Ltd
  • Chugai Pharmaceutical Co Ltd
  • CSPC Pharmaceutical Group Limited
  • Curaxys SL
  • Cytori Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Debiopharm International SA
  • Deciphera Pharmaceuticals LLC
  • Dr. Reddy's Laboratories Ltd
  • Eddingpharm Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • EOS Biosciences Inc
  • Erytech Pharma SA
  • Esperance Pharmaceuticals Inc
  • Exelixis Inc
  • F-star Biotechnology Ltd
  • F. Hoffmann-La Roche Ltd
  • Fate Therapeutics Inc
  • Five Prime Therapeutics Inc
  • Frost Biologic Inc
  • Genelux Corp
  • Genentech Inc
  • Genmab A/S
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • GlycoNex Inc
  • Glycotope GmbH
  • Halozyme Therapeutics Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Harbin Gloria Pharmaceuticals Co Ltd
  • Horizon Pharma Plc
  • Humanigen Inc
  • Hummingbird Bioscience Pte Ltd
  • Hutchison MediPharma Ltd
  • Ignyta Inc
  • Ildong Pharmaceutical Co Ltd
  • Immunomedics Inc
  • Immunomet Therapeutics Inc
  • Incyte Corp
  • Inovio Pharmaceuticals Inc
  • Inspyr Therapeutics Inc
  • Intezyne Technologies Inc
  • Ipsen SA
  • Jiangsu Hengrui Medicine Co Ltd
  • Jiangsu Kanion Pharmaceutical Co Ltd
  • Johnson & Johnson
  • Jounce Therapeutics Inc
  • JW Pharmaceutical Corp
  • Kazia Therapeutics Ltd
  • Konruns Pharmaceutical Co Ltd
  • Kringle Pharma Inc
  • Kyowa Hakko Kirin Co Ltd
  • LATITUDE Pharmaceuticals Inc
  • Leap Therapeutics Inc
  • LegoChem Biosciences Inc
  • LinXis BV
  • Lycera Corp
  • MacroGenics Inc
  • Madrigal Pharmaceuticals Inc.
  • MaxiVAX SA
  • Mebiopharm Co Ltd
  • MedImmune LLC
  • Merck & Co Inc
  • Merck KGaA
  • Merrimack Pharmaceuticals Inc
  • Mersana Therapeutics Inc
  • Merus NV
  • Mirati Therapeutics Inc
  • Moderna Therapeutics Inc
  • Molecular Partners AG
  • Molecular Targeting Technologies Inc
  • Moleculin Biotech Inc
  • Mycenax Biotech Inc
  • NanoCarrier Co Ltd
  • Novartis AG
  • OBI Pharma Inc
  • Oncobiologics Inc
  • Oncolys BioPharma Inc
  • OncoMed Pharmaceuticals Inc
  • OncoResponse Inc
  • Ono Pharmaceutical Co Ltd
  • Opsona Therapeutics Ltd
  • Patrys Ltd
  • Pfizer Inc
  • Pharma Mar SA
  • Pieris Pharmaceuticals Inc
  • Prescient Therapeutics Ltd
  • Puma Biotechnology Inc
  • Redx Pharma Plc
  • Rhizen Pharmaceuticals SA
  • Richter Gedeon Nyrt
  • Sanofi
  • Scancell Holdings Plc
  • Selecta Biosciences Inc
  • SELLAS Life Sciences Group Inc
  • Sequella Inc
  • Shanghai Henlius Biotech Co Ltd
  • Shionogi & Co Ltd
  • Siamab Therapeutics Inc
  • Simcere Pharmaceutical Group
  • Sorrento Therapeutics Inc
  • Spectrum Pharmaceuticals Inc
  • Stelic Institute & Co
  • Supratek Pharma Inc
  • SynCore Biotechnology Co Ltd
  • Synthon Holdings BV
  • Taiho Pharmaceutical Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Takis Srl
  • Tarveda Therapeutics Inc
  • Terns Pharmaceuticals Inc
  • Tessa Therapeutics Pte Ltd
  • Transgene SA
  • United BioPharma Inc
  • Vaxon Biotech
  • Viracta Therapeutics Inc
  • Wuhan YZY Biopharma Co Ltd
  • XuanZhu Pharma Co Ltd
  • Zhejiang Jianfeng Group Company Ltd
  • Zymeworks Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll